Research Center
By connecting with JW Group’s research center,
JW EUVIPHARM J.S.C plans to develop new technology that is
one step ahead of others, and to build key technical
skills with international competitiveness.
JW Euvipharm Joint Stock Company established a comprehensive research center in 1983, based on its accumulated technology and excellent capabilities. With Japan’s Chugai Pharmaceutical, it jointly established C&C New Drug Research Institute, which is the first joint venture in the pharmaceutical Industry in Korea, and JW THERIAC Pharmaceutical Corp., which is a research institute that focuses on studying chemical genomics.
In the 21st century, we will take the lead in the development of world-class innovative new drugs, using a strategy that focuses on exploratory research with the goal of developing personalized therapeutics suitable for the post-genome era.
-
Seocho-gu, SeoulDrug Discovery Center
Core foundation technique :
Anti-cancer therapy/Regenerative medicine- – Pepetidomimetic chemical library
- – WNT modulator for anticancer and tissue regeneration
Seocho-gu, SeoulPharmaceutical Technology Research Center
Core foundation technique :
IMD, New Formulation- – Controlled Release (SMEDDS, Multi-layered Coating)
- – Fixed-Dose Combination
- – New Salts Formulation
- – Formulation Change
Seocho-gu, SeoulAPI Research Center
Core foundation technique :
Process Development of NCE, IMD and Generic /
API Development- – Process Development of NCE (Salt Selection, Polymorphism)
- – High Potency Drug (Peptide, Steroid)
- – High Value-added New Technology (High-quality Purification Technology, Continuous Flow Reaction)
-
Suwon-si, Gyeonggi
C&C Research Laboratories
Core foundation technique :
Immunology/Oncology- – Structure-based drug discovery
- – Onco-panel assay and data base
-
Seattle, USA
JW Theriac
Core foundation technique :
Target-Based Drug Discovery- – High-throughput screening (HTS) system
- – Epigenetic drug discovery
